BioStock: Awareness around arthritis raised for the 24:th consecutive year
October 12th is World Arthritis Day, a global awareness day for rheumatic and musculoskeletal diseases. Malmö based Cyxone’s drug candidate Rabeximod is a disease modifying treatment for rheumatoid arthritis, a disease affecting well over 4 million patients worldwide. The goal is to provide patients with safe but effective treatment that can be conveniently taken and not only treat symptoms but importantly stop damage to the joints before extensive irreversible damage occurs. The company is in the process of designing a phase II trial for Rabeximod which is anticipated to start in the latter part of 2021.
Read the article about the World Arthritis Day 2020 and Cyxone at biostock.se
This is a press release from BioStock - Connecting Innovation & Captial, https://www.biostock.se